There are several definitions of neutralization, two of which are widely accepted
The FDAs current guidance, updated June 15, 2026, is blunt about what the category means: compounded GLP-1s skip the agencys review for safety, effectiveness, and quality entirely, and as of May 31, 2026 the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, per the FDAs compounded GLP-1 page
Combines skincare with sun care for all-around lip protection
GLP-1RAs also reduce hepatic steatosis, circulating triacylglycerol, and low-density lipoprotein cholesterol concentrations and effectively reduce blood pressure [25]
It previously had a twice-daily pill that was also scrapped after similar liver concerns in 2023